CORT

SEC source: 0001193125-26-382475 · ownership.xml · nonDerivative · entry 2

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,313

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382475 · ownership.xml · nonDerivative · entry 1

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,149

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · derivative · entry 13

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 66,986

Underlying: Common Stock · 25,000 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F17 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 6

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,055

F8 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 5

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,905

F6 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F7 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 4

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,755

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.37 to $115.82 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 3

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,036

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.365 to $115.295 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,025

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.36 to $114.34 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382474 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,755

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382463 · ownership.xml · nonDerivative · entry 2

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,406

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382463 · ownership.xml · nonDerivative · entry 1

Mokari Atabak · CIK 0001678419 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,268

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,754

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382457 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,590

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 2

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,344

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382456 · ownership.xml · nonDerivative · entry 1

Vieira Roberto Wandenkolk · CIK 0002150104 · President, Oncology

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,206

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382450 · ownership.xml · nonDerivative · entry 2

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,755

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-382450 · ownership.xml · nonDerivative · entry 1

Lyon Joseph Douglas · CIK 0001817838 · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,625

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 398 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 537 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-374607 · ownership.xml · derivative · entry 4

Park Kimberly · CIK 0001788208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2029-09-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 3

Park Kimberly · CIK 0001788208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $122.50 to $122.80 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

SEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 2

Park Kimberly · CIK 0001788208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,685

F1 · kind: These shares were withheld by the Issuer in order to cover the exercise price in connection with the net exercise of stock options reported herein.

SEC source: 0001193125-26-374607 · ownership.xml · nonDerivative · entry 1

Park Kimberly · CIK 0001788208 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001193125-26-371388 · ownership.xml · derivative · entry 9

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 169,045

Underlying: Common Stock · 30,955 shares

Expires 2029-02-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-371388 · ownership.xml · nonDerivative · entry 3

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,755

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $126.00 to $126.23 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-371388 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,625

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $125.00 to $125.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-371388 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,710

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 4

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Disclosed balance after: 1,133,539

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $119.605 to $119.6775. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 3

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Disclosed balance after: 1,133,939

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $118.60 to $119.345. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 2

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Disclosed balance after: 1,140,994

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $117.60 to $118.595. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001193125-26-359255 · ownership.xml · nonDerivative · entry 1

MAHONEY DAVID L · CIK 0001224091 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · Held by David L. Mahoney and Winnifred C. Ellis 1998 Family Trust

Disclosed balance after: 1,232,161

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on May 11, 2026 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.595 to $117.59. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

SEC source: 0001193125-26-355560 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Gary Charles Robb TTE Robb Revocable Trust

Disclosed balance after: 39,716

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $116.00 to $116.54 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3 · ownership.nature: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.

SEC source: 0001193125-26-355560 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,426

F1 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-355563 · ownership.xml · derivative · entry 8

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 91,986

Underlying: Common Stock · 3,664 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-355563 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,755

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-355563 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 3

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,074,543

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.51 to $112.83 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 2

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,076,822

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.01 to $112.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-355562 · ownership.xml · nonDerivative · entry 1

WILSON JAMES N · CIK 0001236387 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust

Disclosed balance after: 1,081,490

F1 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on March 12, 2026 in effect at the time of this transaction.

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.00 to $110.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F5 · ownership.nature: Reporting Person has voting power over the shares held by the James N. Wilson and Pamela D. Wilson Trust pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.

SEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 15,571

F3 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

SEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 15,571

F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

SEC source: 0001193125-26-352428 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,551

F1 · balance_after: Includes 251 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-346951 · ownership.xml · derivative · entry 8

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,650

Underlying: Common Stock · 1,031 shares

Expires 2027-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-346951 · ownership.xml · nonDerivative · entry 2

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,755

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 8, 2025 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.50 to $114.58 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-346951 · ownership.xml · nonDerivative · entry 1

Maduck Sean · CIK 0001698310 · See Remarks

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,786

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 228 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 205 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 454 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 615 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-346942 · ownership.xml · derivative · entry 4

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 16,300 shares

Expires 2031-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 3

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,985

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 2

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,755

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-346942 · ownership.xml · nonDerivative · entry 1

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,285

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-338637 · ownership.xml · derivative · entry 3

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 126,300

Underlying: Common Stock · 3,700 shares

Expires 2031-09-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

SEC source: 0001193125-26-338637 · ownership.xml · nonDerivative · entry 2

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,985

F2 · kind: This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.92 to $113.455 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

SEC source: 0001193125-26-338637 · ownership.xml · nonDerivative · entry 1

Guyer William · CIK 0001879013 · Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,685

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.